1. Anderson NG, Li P, Marsden LA, Williams N, Roberts TM, et al. Raf-1 is a potential substrate for mitogen-activated protein kinase in vivo. Biochem J 1991;277:573-6.

2. Morrison DK, Kaplan DR, Rapp U, Roberts TM. Signal transduction from membrane to cytoplasm: growth factors and membrane-bound oncogene products increase Raf-1 phosphorylation and associated protein kinase activity. Proc Natl Acad Sci U S A 1988;85:8855-9.

3. Dent P, Haser W, Haystead TA, Vincent LA, Roberts TM, et al. Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro. Science 1992;257:1404-7.

4. Kyriakis JM, App H, Zhang XF, Banerjee P, Brautigan DL, et al. Raf-1 activates MAP kinase-kinase. Nature 1992;358:417-21.

5. L’Allemain G, Sturgill TW, Weber MJ. Defective regulation of mitogen-activated protein kinase activity in a 3T3 cell variant mitogenically nonresponsive to tetradecanoyl phorbol acetate. Mol Cell Biol 1991;11:1002-8.

6. Leevers SJ, Marshall CJ. Activation of extracellular signal-regulated kinase, ERK2, by p21ras oncoprotein. EMBO J 1992;11:569-74.

7. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A 1995;92:7686-9.

8. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995;270:27489-94.

9. Pan BT, Zhang Y, Brott B, Chen DH. The 96 kDa protein kinase activated by oncogenic Ras in Xenopus egg extracts is also activated by constitutively active Mek: activation requires serine/threonine phosphorylation. Oncogene 1997;14:1653-60.

10. Börsch-Haubold AG, Pasquet S, Watson SP. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J Biol Chem 1998;273:28766-72.

11. Adderley SR, Fitzgerald DJ. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase-2. J Biol Chem 1999;274:5038-46.

12. Suzaki Y, Yoshizumi M, Kagami S, Koyama AH, Taketani Y, et al. Hydrogen peroxide stimulates c-Src-mediated big mitogen-activated protein kinase 1 (BMK1) and the MEF2C signaling pathway in PC12 cells: potential role in cell survival following oxidative insults. J Biol Chem 2002;277:9614-21.

13. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273:18623-32.

14. Duncia JV, Santella JB 3rd, Higley CA, Pitts WJ, Wityak J, et al. MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg Med Chem Lett 1998;8:2839-44.

15. Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller-Schenck D, et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open 2019;4:e000491.

16. Steeb T, Wessely A, Ruzicka T, Heppt MV, Berking C. How to MEK the best of uveal melanoma: a systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma. Eur J Cancer 2018;103:41-51.

17. Hotte SJ, Hirte HW. BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr Pharm Des 2002;8:2249-53.

18. Wilhelm S, Chien DS. BAY 43-9006: preclinical data. Curr Pharm Des 2002;8:2255-7.

19. Hilger RA, Kredke S, Hedley D, Moeller JG, Bauer RJ, et al. ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006. Int J Clin Pharmacol Ther 2002;40:567-8.

20. Rahmani M, Davis EM, Bauer C, Dent P, Grant S. Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem 2005;280:35217-27.

21. Panka DJ, Wang W, Atkins MB, Mier JW. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 2006;66:1611-9.

22. Schöffski P, Dumez H, Clement P, Hoeben A, Prenen H, et al. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol 2006;17:1185-96.

23. Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (Barc) 2005;41:773-84.

24. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98:326-34.

25. Lierman E, Folens C, Stover EH, Mentens N, Van Miegroet H, et al. Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant. Blood 2006;108:1374-6.

26. Rahmani M, Davis EM, Crabtree TR, Habibi JR, Nguyen TK, et al. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol 2007;27:5499-513.

27. Holz MS, Janning A, Renné C, Gattenlöhner S, Spieker T, et al. Induction of endoplasmic reticulum stress by sorafenib and activation of NF-κB by lestaurtinib as a novel resistance mechanism in Hodgkin lymphoma cell lines. Mol Cancer Ther 2013;12:173-83.

28. Martin AP, Park MA, Mitchell C, Walker T, Rahmani M, et al. BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing. Mol Pharmacol 2009;76:327-41.

29. Park MA, Reinehr R, Häussinger D, Voelkel-Johnson C, Ogretmen B, et al. Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells. Mol Cancer Ther 2010;9:2220-31.

30. Bareford MD, Park MA, Yacoub A, Hamed HA, Tang Y, et al. Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res 2011;71:4955-67.

31. Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 2004;64:4309-18.

32. Carón RW, Yacoub A, Li M, Zhu X, Mitchell C, et al. Activated forms of H-RAS and K-RAS differentially regulate membrane association of PI3K, PDK-1, and AKT and the effect of therapeutic kinase inhibitors on cell survival. Mol Cancer Ther 2005;4:257-70.

33. Carón RW, Yacoub A, Zhu X, Mitchell C, Han SI, et al. H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent. Mol Cancer Ther 2005;4:243-55.

34. Bertolotti A, Zhang Y, Hendershot LM, Harding HP, Ron D. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol 2000;2:326-32.

35. Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell 2000;6:1099-108.

36. Lee AS. The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods 2005;35:373-81.

37. Booth L, Cazanave SC, Hamed HA, Yacoub A, Ogretmen B, et al. OSU-03012 suppresses GRP78/BiP expression that causes PERK-dependent increases in tumor cell killing. Cancer Biol Ther 2012;13:224-36.

38. Booth L, Shuch B, Albers T, Roberts JL, Tavallai M, et al. Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function. Oncotarget 2016;7:12975-96.

39. Booth L, Roberts JL, Cash DR, Tavallai S, Jean S, et al. GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human disease. J Cell Physiol 2015;230:1661-76.

40. Booth L, Roberts JL, Tavallai M, Nourbakhsh A, Chuckalovcak J, et al. OSU-03012 and viagra treatment inhibits the activity of multiple chaperone proteins and disrupts the blood-brain barrier: implications for anti-cancer therapies. J Cell Physiol 2015;230:1982-98.

41. Earl PL, Moss B, Doms RW. Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein. J Virol 1991;65:2047-55.

42. Roberts JL, Tavallai M, Nourbakhsh A, Fidanza A, Cruz-Luna T, et al. GRP78/Dna K is a target for nexavar/stivarga/votrient in the treatment of human malignancies, viral infections and bacterial diseases. J Cell Physiol 2015;230:2552-78.

43. Booth L, Roberts JL, Ecroyd H, Tritsch SR, Bavari S, et al. AR-12 inhibits multiple chaperones concomitant with stimulating autophagosome formation collectively preventing virus replication. J Cell Physiol 2016;231:2286-302.

44. Taylor EC, Kuhnt D, Shih C, Rinzel SM, Grindey GB, et al. A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 1992;35:4450-4.

45. Racanelli AC, Rothbart SB, Heyer CL, Moran RG. Therapeutics by cytotoxic metabolite accumulation: pemetrexed causes ZMP accumulation, AMPK activation, and mammalian target of rapamycin inhibition. Cancer Res 2009;69:5467-74.

46. Rothbart SB, Racanelli AC, Moran RG. Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas. Cancer Res 2010;70:10299-309.

47. Tripathi DN, Chowdhury R, Trudel LJ, Tee AR, Slack RS, et al. Reactive nitrogen species regulate autophagy through ATM-AMPK-TSC2-mediated suppression of mTORC1. Proc Natl Acad Sci U S A 2013;110:E2950-7.

48. Corona Velazquez AF, Jackson WT. So many roads: the multifaceted regulation of autophagy induction. Mol Cell Biol 2018;38:e00303-18.

49. Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, et al. The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene 2005;24:6861-9.

50. Zheng W, Xie W, Yin D, Luo R, Liu M, et al. ATG5 and ATG7 induced autophagy interplays with UPR via PERK signaling. Cell Commun Signal 2019;17:42.

51. Simmons JK, Michalowski AM, Gamache BJ, DuBois W, Patel J, et al. Cooperative targets of combined mTOR/HDAC inhibition promote MYC degradation. Mol Cancer Ther 2017;16:2008-21.

52. Dent P, Booth L, Poklepovic A, Hancock JF. Signaling alterations caused by drugs and autophagy. Cell Signal 2019;64:109416.

53. Tao Z, Li SX, Shen K, Zhao Y, Zeng H, et al. Safety and efficacy profile of neratinib: a systematic review and meta-analysis of 23 prospective clinical trials. Clin Drug Investig 2019;39:27-43.

54. Roskoski R Jr. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res 2019;139:395-411.

55. Tagliamento M, Genova C, Rijavec E, Rossi G, Biello F, et al. Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. Expert Opin Pharmacother 2018;19:2055-62.

56. Tavallai M, Booth L, Roberts JL, Poklepovic A, Dent P. Rationally repurposing ruxolitinib [Jakafi (®)] as a solid tumor therapeutic. Front Oncol ;6:142.

57. Booth L, Roberts JL, Tavallai M, Webb T, Leon D, et al. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling. Oncotarget 2016;7:19620-30.

58. Booth L, Roberts JL, Poklepovic A, Avogadri-Connors F, Cutler RE, et al. HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo. Oncotarget 2017;8:90262-77.

59. Booth L, Roberts JL, Poklepovic A, Dent P. NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cells. Oncol Signal 2018;1:19-30.

60. Davis MI, Hunt JP, Herrgard S, Ciceri P, Wodicka LM, et al. Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol 2011;29:1046-51.

61. Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, et al. The target landscape of clinical kinase drugs. Science 2017;358:eaan4368.

62. Schuster SC, Swanson RV, Alex LA, Bourret RB, Simon MI. Assembly and function of a quaternary signal transduction complex monitored by surface plasmon resonance. Nature 1993;365:343-7.

63. Booth L, Roberts JL, Sander C, Lalani AS, Kirkwood JM, et al. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gαq and Gα11 and kill uveal melanoma cells. Cancer Biol Ther 2019;20:700-10.

64. Booth L, Roberts JL, Poklepovic A, Kirkwood J, Sander C, et al. The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1/ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib. Cancer Biol Ther 2018;19:132-7.

65. Booth L, Roberts JL, Rais R, Cutler RE Jr, Diala I, et al. Neratinib augments the lethality of [regorafenib + sildenafil]. J Cell Physiol 2019;234:4874-87.

66. Cho KJ, Casteel DE, Prakash P, Tan L, van der Hoeven D, et al. AMPK and endothelial nitric oxide synthase signaling regulates K-Ras plasma membrane interactions via cyclic GMP-dependent protein kinase 2. Mol Cell Biol 2016;36:3086-99.

67. Waters AM, Ozkan-Dagliyan I, Vaseva AV, Fer N, Strathern LA, et al. Evaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies. Sci Signal 2017;10:eaao3332.

68. Dent P, Booth L, Roberts JL, Liu J, Poklepovic A, et al. Neratinib inhibits Hippo/YAP signaling, reduces mutant K-RAS expression, and kills pancreatic and blood cancer cells. Oncogene 2019;38:5890-904.

69. Hobert ME, Friend LA, Carlin CR. Regulation of EGF signaling by cell polarity in MDCK kidney epithelial cells. J Cell Physiol 1999;181:330-41.

70. Thompson BJ, Sahai E. MST kinases in development and disease. J Cell Biol 2015;210:871-82.

71. Chen S, Fang Y, Xu S, Reis C, Zhang J. Mammalian sterile20-like kinases: signalings and roles in central nervous system. Aging Dis 2018;9:537-52.

72. Wang OH, Azizian N, Guo M, Capello M, Deng D, et al. Prognostic and functional significance of MAP4K5 in pancreatic cancer. PLoS One 2016;11:e0152300.

73. Meng Z, Moroishi T, Mottier-Pavie V, Plouffe SW, Hansen CG, et al. MAP4K family kinases act in parallel to MST1/2 to activate LATS1/2 in the Hippo pathway. Nat Commun 2015;6:8357.

74. Hsu CL, Lee EX, Gordon KL, Paz EA, Shen WC, et al. MAP4K3 mediates amino acid-dependent regulation of autophagy via phosphorylation of TFEB. Nat Commun 2018;9:942.

75. Booth L, Roberts JL, Tavallai M, Chuckalovcak J, Stringer DK, et al. [Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling. Oncotarget 2016;7:23608-32.

76. Booth L, Albers T, Roberts JL, Tavallai M, Poklepovic A, et al. Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo. Oncotarget 2016;7:40398-417.

77. Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther 2005;4:677-85.

78. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-72.

79. Tavallai M, Hamed HA, Roberts JL, Cruickshanks N, Chuckalovcak J, et al. Nexavar/Stivarga and viagra interact to kill tumor cells. J Cell Physiol 2015;230:2281-98.

80. Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014;370:2286-94.

81. Yamaguchi F, Kato E, Wakabayashi A, Shikama Y. Effect of osimertinib treatment on lung adenocarcinoma with squamous cell transformation harboring the T790M mutation: a case report and literature review. Mol Clin Oncol 2019;11:127-31.

82. Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, et al. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. Clin Cancer Res 2018;24:6195-203.

Cancer Drug Resistance
ISSN 2578-532X (Online)


All published articles will preserved here permanently:


All published articles will preserved here permanently: